Many authors suggest that it is not only the inhibition of COX-2 but the regulation of other factors involved in the development of malignant tumours by the drug that has a considerable impact on hindering tumour growth (i.e., a decrease in OCT4, SOX2, and BMP7 gene expression, increase in the expression of E-cadherin gene, Wnt/β-catenin, cell adhesion molecules, and surface receptors: AMFR and EGFR, induction of p53 gene expression) [39]. The gene discussed is CDH1; the disease is cancer.